Allspring Global Investments Holdings LLC Sells 16,683 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Allspring Global Investments Holdings LLC lessened its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 40.7% in the third quarter, Holdings Channel.com reports. The firm owned 24,263 shares of the company’s stock after selling 16,683 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Amphastar Pharmaceuticals were worth $1,177,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 2,815,596 shares of the company’s stock valued at $174,145,000 after acquiring an additional 48,203 shares in the last quarter. Hussman Strategic Advisors Inc. purchased a new position in shares of Amphastar Pharmaceuticals in the first quarter valued at $2,766,000. Nordea Investment Management AB raised its holdings in Amphastar Pharmaceuticals by 0.4% during the 1st quarter. Nordea Investment Management AB now owns 333,014 shares of the company’s stock valued at $14,802,000 after buying an additional 1,209 shares during the period. Mutual of America Capital Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 11.3% during the 1st quarter. Mutual of America Capital Management LLC now owns 97,683 shares of the company’s stock worth $4,289,000 after acquiring an additional 9,926 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S raised its position in Amphastar Pharmaceuticals by 62.9% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 12,455 shares of the company’s stock valued at $547,000 after purchasing an additional 4,811 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $50.53 on Friday. The firm has a 50 day moving average price of $48.17 and a 200 day moving average price of $43.72. The company has a market cap of $2.47 billion, a price-to-earnings ratio of 17.48, a PEG ratio of 0.88 and a beta of 0.83. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. The business had revenue of $182.39 million for the quarter, compared to analysts’ expectations of $171.29 million. Sell-side analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current year.

Insider Activity

In related news, Director Richard K. Prins sold 17,101 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the sale, the director now owns 33,971 shares in the company, valued at approximately $1,463,130.97. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Richard K. Prins sold 17,101 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the transaction, the director now directly owns 33,971 shares in the company, valued at approximately $1,463,130.97. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now owns 75,409 shares of the company’s stock, valued at approximately $3,504,256.23. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,101 shares of company stock worth $1,069,350. 27.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 18th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.